Benefit in lung function improvement and side-effect profile of long-term responders: An analysis of 14 NSCLC patients treated for at least 9 months with gefitinib
Keywords: جفیتینیب، ایرسا; NSCLC; EGFR inhibition; Gefitinib; Iressaâ¢; Lung function;